George Rederich
Neurology · Redondo Beach, CANPI 1649212309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 39.7% of the total. Reporting peaked in 2019 at $912 and has fallen 59.3% since, to $371 in 2023.
Across 195 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$518
- Teva Pharmaceuticals USA, Inc.$354
- Amgen$123
- Biogen$94
- Upsher-smith Laboratories LLC$65
- plus $597 from 22 others
Across 84 payments — averaging $3221.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$269K
- Teva Pharmaceuticals USA, Inc.$2K
What the payments were for
- Speaking & faculty fees$231%
- Food & beverage$2,87799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 109 | $1,150 |
| Novartis | 35 | $518 |
| Teva Pharmaceuticals USA, Inc. | 10 | $354 |
| Amgen | 4 | $123 |
| Biogen | 5 | $94 |
| Upsher-smith Laboratories LLC | 3 | $65 |
| Promius Pharma LLC | 2 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Bausch Health US, LLC | 2 | $49 |
| Amneal Pharmaceuticals LLC | 2 | $46 |
| Lundbeck LLC | 2 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Harmony Biosciences LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Adamas Pharmaceuticals, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Abbott | 1 | $20 |
| Tanabe Pharma America, Inc. | 1 | $20 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Pfizer | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$121
How this compares
$2,900 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $11,993 |
| Memantine Hcl | 25 | $1,602 |
| Gabapentin | 57 | $995 |
| Quetiapine Fumarate | 11 | $656 |
| Propranolol Hcl | 19 | $384 |
| Donepezil Hcl | 34 | $361 |
| RizatriptanRizatriptan Benzoate | 39 | $359 |
| Lamotrigine | 14 | $192 |
| Sumatriptan Succinate | 27 | $154 |
Paid to pharmacies, not to this prescriber.
Other neurology in Redondo Beach
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.